Liraglutide is an FDA-approved, once-daily injection that activates a single receptor, GLP-1. Retatrutide is an investigational, once-weekly injection that activates three receptors (GIP, GLP-1, and glucagon) and is still in clinical trials. Liraglutide has more than a decade of real-world prescribing history. Retatrutide is a newer, more ambitious molecule whose long-term safety and effectiveness are still being studied.
The Short Answer: Five Differences That Matter
Retatrutide and liraglutide both belong to the incretin family, but they sit at opposite ends of its timeline. Here is the side-by-side:
- Receptors targeted: Liraglutide activates GLP-1 only. Retatrutide activates GIP, GLP-1, and glucagon receptors.
- Regulatory status: Liraglutide is FDA-approved, sold as Victoza for blood sugar management in adults with type 2 diabetes and as Saxenda for chronic weight management. Retatrutide is not approved anywhere. As of this writing, it is in Phase 3 trials.
- Dosing schedule: Liraglutide is injected once daily. Retatrutide is being studied as a once-weekly injection.
- Developer: Novo Nordisk developed liraglutide. Eli Lilly is developing retatrutide.
- Evidence base: Liraglutide has years of trial data and real-world use behind it. Retatrutide has published Phase 2 data and ongoing Phase 3 programs.
In plain terms, liraglutide is a known quantity. Retatrutide is a promising candidate that has not finished the approval process. For a deeper look at each one, see our guides to liraglutide benefits and retatrutide benefits.
Mechanism: One Receptor vs. Three
Liraglutide copies one gut hormone. Retatrutide is engineered to act on three hormone pathways at once.
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It signals the pancreas to release insulin when blood sugar rises. It also slows how fast the stomach empties and acts on appetite centers in the brain. Liraglutide is a modified version of human GLP-1. A fatty acid chain helps it bind to albumin in the blood, so it lasts far longer than natural GLP-1, which breaks down within minutes.
Retatrutide adds two more targets:
- GIP (glucose-dependent insulinotropic polypeptide): another gut hormone involved in insulin release after meals. Researchers are studying how it may interact with fat tissue and appetite signaling.
- Glucagon: usually thought of as the hormone that raises blood sugar. Researchers are interested in glucagon receptor activity because it may influence energy expenditure and how the liver handles fat. In a triple agonist, the GLP-1 and GIP activity is designed to balance glucagon's effect on blood sugar.
The idea behind a triple agonist is that combining these signals could produce larger metabolic effects than any single pathway. That is a hypothesis being tested in trials. It is not yet a settled conclusion.
Development Stage: Approved Drug vs. Investigational Compound
This is the single most important difference: liraglutide is a prescription medication you can legally get from a doctor, and retatrutide is not.
Liraglutide was first approved in the U.S. in 2010 for blood sugar management. A higher-dose version for chronic weight management followed in 2014. Because it has been on the market so long, doctors understand its side effect profile, its drug interactions, and which patients it does or does not suit. Generic versions of liraglutide have also begun to appear in the U.S.
Retatrutide (code name LY3437943) is in late-stage development. Eli Lilly's Phase 3 program is studying it across several populations. A Phase 2 trial published in 2023 drew wide attention for the size of the weight changes reported, which is why so many people now search for this drug. Phase 2 results are an early signal, though, not a final verdict. Phase 3 trials are larger and longer, and they are designed to confirm both benefit and safety.
A warning about online sellers: Some websites sell "retatrutide" labeled "for research use only." These products are not approved for human use. They are not made under pharmaceutical oversight, and their purity, dose, and identity cannot be verified. Buying them carries real risk.
Dosing Schedule and Pharmacology
Liraglutide is a daily shot. Retatrutide is designed as a weekly shot.
Liraglutide's half-life is roughly 13 hours. That is long compared with natural GLP-1 but short compared with newer drugs, so it needs a daily injection. It is started at a low dose and stepped up gradually under a prescriber's direction, mainly to help the body adjust to gastrointestinal effects.
Retatrutide was built for a much longer half-life, which supports once-weekly dosing in trials. Trial protocols have also used gradual dose escalation. Dosing outside a clinical trial has no approved basis, because there is no approved label.
For many people, convenience is a practical difference. One injection a week instead of seven is a big reason newer incretin drugs have gained ground. That convenience does not tell you anything about safety or suitability, though. Those questions belong with a licensed clinician.
What the Research Shows, and What It Doesn't
Liraglutide has an established, well-characterized evidence base. Retatrutide's early data look strong, but key questions are still open.
What we can reasonably say:
- Liraglutide has been studied in large, long-term trials and in years of clinical practice. Its effects on blood sugar, appetite, and body weight are well documented, and so are its limits.
- Retatrutide's Phase 2 data suggested larger average weight changes than older single-agonist drugs produced in their own trials. That finding drives most of the current interest.
What we cannot say yet:
- No published head-to-head trial has directly compared retatrutide with liraglutide. Comparing results across separate trials is unreliable, because the populations, durations, and designs differ.
- Long-term safety of retatrutide is not established. Rare side effects often show up only after thousands of people have used a drug for years.
- Durability is unclear. We don't yet know how retatrutide's effects hold up over long periods or after someone stops treatment.
Anyone who tells you retatrutide is definitively "better" than liraglutide is getting ahead of the evidence. A fair framing is that retatrutide is a more potent-looking candidate still under study, while liraglutide is a proven option with known trade-offs.
Side Effects and Safety Considerations
Both drugs share the gastrointestinal side effects common to the incretin class. Retatrutide's full safety profile is still being defined.
With liraglutide, the most commonly reported effects are nausea, vomiting, diarrhea, constipation, and reduced appetite. These are often strongest during dose escalation. Its label carries a boxed warning based on thyroid C-cell tumors seen in rodent studies. It is not recommended for people with certain personal or family histories of thyroid tumors. The label also lists warnings related to the pancreas, the gallbladder, and the kidneys.
Retatrutide trials have reported similar gastrointestinal effects. Researchers have also watched closely for changes in heart rate and other cardiovascular measures, since multi-receptor drugs can act on the body in several ways. Because the drug is investigational, there is no approved label, and the full list of warnings is not yet known.
The takeaway is simple. These are powerful prescription drugs that require medical supervision. They are not lifestyle products, and neither should be used without a clinician's guidance.
Where Each Fits in the Incretin Timeline
Liraglutide is the first generation. Retatrutide is the leading edge of the newest generation.
The class has moved through several stages:
1. Daily GLP-1 agonists, with liraglutide as the best-known example. 2. Weekly GLP-1 agonists, such as semaglutide, which kept the single target but extended dosing to once a week. 3. Dual agonists, such as tirzepatide, which act on both GIP and GLP-1. 4. Triple agonists, with retatrutide as the most prominent candidate, adding glucagon to the mix.
Each step has aimed at greater convenience, stronger metabolic effects, or both. This progression explains why retatrutide gets so much attention. It also explains why liraglutide still matters: it is the reference point that later drugs are measured against, and it offers a long safety record that newer drugs have not had time to build.
Supplements Are Not GLP-1 Drugs
No dietary supplement is a GLP-1 drug, a triple agonist, or a substitute for either one. Retatrutide and liraglutide are pharmaceutical peptides that act directly on hormone receptors at prescription doses. Supplements are regulated differently, work differently, and should never be framed as alternatives to prescribed medication.
If you are taking, or considering, an incretin medication, that decision belongs with your doctor. If you are not a candidate for these drugs, or simply want to build healthier daily habits, the fundamentals carry the most weight: protein-forward meals, fiber, strength training, sleep, and consistent movement.
Some people choose to add supplements that support those habits. For example, GlucoMend Glucose Stabilizer is formulated to support healthy glucose metabolism as part of a balanced diet. Ageless Humans makes every product in its FDA-registered facility in Carlsbad, California, and third-party lab tests every lot, with a Certificate of Analysis for each. If you take any prescription medication, including a GLP-1 drug, check with your clinician before adding a supplement.
Frequently asked questions
What is the main difference between retatrutide and liraglutide?+
Liraglutide activates one receptor (GLP-1) and is an FDA-approved, once-daily injection. Retatrutide activates three receptors (GIP, GLP-1, and glucagon) and is an investigational once-weekly injection still in clinical trials. Liraglutide has more than a decade of real-world use. Retatrutide's long-term safety and effectiveness are still being studied.
Is retatrutide FDA-approved?+
No. As of this writing, retatrutide is not approved by the FDA or any other major regulator. It is in Phase 3 clinical trials run by Eli Lilly. Products sold online as "research-use" retatrutide are not approved for human use, and their quality cannot be verified.
Is retatrutide stronger than liraglutide?+
Early Phase 2 data suggested retatrutide may produce larger average weight changes than older single-agonist drugs. However, no head-to-head trial has directly compared the two, and comparisons across separate trials are unreliable. Retatrutide's long-term safety is also not yet established, so "stronger" does not mean "better" for any given person.
Why is liraglutide taken daily while retatrutide is weekly?+
Liraglutide has a half-life of roughly 13 hours, so it needs a daily injection to maintain its effect. Retatrutide was designed with a much longer half-life, which allows once-weekly dosing in clinical trials. The schedule reflects how each molecule was engineered. It says nothing about which one is safer or more suitable.
Do retatrutide and liraglutide have the same side effects?+
Both share the gastrointestinal effects common to incretin drugs, such as nausea, vomiting, diarrhea, and constipation. Liraglutide has a known label that includes a boxed warning about thyroid C-cell tumors seen in rodent studies. Retatrutide has no approved label yet, and researchers are still characterizing its full safety profile, including effects on heart rate.
Can a supplement work like retatrutide or liraglutide?+
No. Retatrutide and liraglutide are prescription pharmaceutical peptides that act directly on hormone receptors. Dietary supplements are not GLP-1 drugs and are not substitutes for them. Some supplements are formulated to support healthy metabolism alongside diet and exercise, but anyone on or considering a prescription medication should talk to a clinician first.
